Progress in precision diagnostic and therapeutic technologies for tumor-related ocular diseases: improving patients′ life quality
10.3760/cma.j.cn431274-20250707-00496
- VernacularTitle:重视肿瘤相关眼病的精准诊疗技术进展，提高患者生存质量
- Author:
Youxin CHEN
1
;
Nien LI
1
;
Erqian WANG
1
Author Information
1. 中国医学科学院 北京协和医院眼科，北京 100730
- Publication Type:Journal Article
- Keywords:
Tumor-related ocular diseases;
Precision diagnosis and treatment;
Ocular adverse events of anti-tumor drugs
- From:
Journal of Chinese Physician
2025;27(5):641-644
- CountryChina
- Language:Chinese
-
Abstract:
Malignant tumors can invade ocular tissues or cause reactive ocular lesions through distant metastasis or immune response. Anti-tumor drugs have brought breakthroughs to treatment, while also posing new challenges of adverse ocular reactions. Current precision diagnosis and treatment of patients with tumor-related ocular diseases is undergoing technological and strategic innovations. In the diagnostic aspect, multimodal ophthalmic imaging technology facilitates the identification and monitoring of ocular lesions. Minimally invasive biopsy enhances the level of pathological diagnosis. Molecular markers and artificial intelligence (AI) strengthen the ability of differential diagnosis and prognosis prediction. In the therapeutic aspect, local precise radiotherapy reduces damage to surrounding tissues, and systemic therapies require strategies to overcome the limitations of the blood-ocular barrier. In the management of ocular adverse events caused by anti-tumor drugs, it is necessary to balance tumor control and visual preservation, emphasizing dynamic surveillance and early warning. Future studies in diagnosis and treatment will focus on multimodal data integration, molecular targeting technologies, and intelligent decision-making systems, aiming to establish comprehensive management frameworks encompassing multidisciplinary coordination, full disease-cycle monitoring, and personalized interventions to achieve the precision medical goal of " visual survival" .
